美国TAVR患者红细胞输注趋势与结局
该研究利用美国全国住院患者样本数据库,分析2012年1月至2015年9月46,710例经导管主动脉瓣置换术(TAVR)患者。结果显示红细胞输注率从2012年第一季度的29.5%降至2015年第三季度的10.8%(P<.001)。倾向匹配分析表明,在无出血患者中红细胞输注与院内死亡、感染和短暂性脑缺血发作/卒中风险增加相关,而在有明显出血患者中无此关联。
要点
- TAVR患者红细胞输注率从2012年29.5%降至2015年10.8%(P<.001)
- 无出血TAVR患者中,红细胞输注与院内死亡风险增加相关(OR 2.29)
- 有明显出血TAVR患者中,红细胞输注与不良结局无显著关联
核心结论
- 在无出血的TAVR患者中,红细胞输注与更差的临床结局相关,但在有明显出血的患者中无此关联。
- TAVR患者红细胞输注的效用和最佳阈值,尤其是有明显出血者,需进一步前瞻性研究。
研究设计与样本
- 回顾性队列研究,使用美国全国住院患者样本数据库,识别2012年1月至2015年9月间的TAVR手术。
- 共纳入46,710例TAVR手术,按有无明显出血分层进行倾向性匹配,比较输血组与非输血组的院内结局(匹配队列7995对)。
主要发现
- 研究期间红细胞输注率为17.3%(95%CI 16.1%-18.5%)。
- 红细胞输注率从2012年第一季度的29.5%显著下降至2015年第三季度的10.8%(P<.001)。
- 高龄、女性、外周血管疾病、慢性肾脏病、贫血、凝血病、液体/电解质紊乱与输血 odds 增加相关;择期入院、肥胖、血管内入路与输血 odds 降低相关。
- 在无出血的匹配队列中,红细胞输注与院内死亡(OR 2.29,95%CI 1.31-4.02)、感染(OR 2.13,95%CI 1.03-4.39)、TIA/卒中(OR 3.36,95%CI 1.52-7.45)风险增加相关。
- 在有明显出血的匹配队列中,红细胞输注与院内死亡(OR 1.10,95%CI 0.68-1.48)、感染(OR 0.80,95%CI 0.45-1.45)、TIA/卒中(OR 1.16,95%CI 0.74-1.85)无显著关联;交互作用P<.05。
临床怎么用
- 在无出血的TAVR患者中,应审慎评估红细胞输注的必要性,因其与不良结局相关。
- 对于有明显出血的TAVR患者,红细胞输注的决策需个体化,当前证据未显示明确危害。
局限性
- 回顾性研究设计,可能存在未测量的混杂因素。
- 仅使用行政数据库,可能存在编码错误或信息偏倚。
- 缺乏输血阈值、血红蛋白水平等详细临床数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To examine temporal trends, predictors, and outcomes of red blood cell (RBC) transfusion in patients undergoing transcatheter aortic valve replacement (TAVR) in the United States. METHODS: We used the National Inpatient Sample databases to identify TAVR procedures performed between January 2012 and September 2015 in the United States. Patients were propensity matched (within the strata of overt and no bleeding) on the likelihood of receiving RBC transfusion, and in-hospital outcomes were compared between the 2 groups in the matched cohort. RESULTS: Among 46,710 TAVR procedures performed during the study period, rates of RBC transfusion were 17.3% (95% confidence interval [CI], 16.1%-18.5%). RBC transfusion rates decreased significantly from 29.5% during the first quarter of 2012 to 10.8% during the third quarter of 2015 (P < .001). Older age, female sex, peripheral vascular disease, chronic kidney disease, anemia, coagulopathy, and fluid/electrolyte disorders were associated with increased odds, whereas elective admission, obesity, and endovascular access were associated with decreased odds of RBC transfusion. In the propensity-matched cohort (7995 pairs with and without RBC transfusion), RBC transfusion was associated with increased risk of in-hospital mortality, infection, and transient ischemic attack/stroke in patients without bleeding (odds ratio [OR]Mortality, 2.29; 95% CI, 1.31-4.02; ORInfection, 2.13; 95% CI, 1.03-4.39; ORTransient ischemic attack/Stroke, 3.36; 95% CI, 1.52-7.45), but not in those with overt bleeding (ORMortality, 1.10; 95% CI, 0.68-1.48; ORInfection, 0.80; 95% CI, 0.45-1.45; ORTransient ischemic attack/Stroke, 1.16; 95% CI, 0.74-1.85); Pinteraction < .05 for all. CONCLUSIONS: RBC transfusion is associated with worse clinical outcomes in TAVR patients without bleeding, but not in those with overt bleeding. The utility and optimal threshold for RBC transfusion in TAVR patients, especially among those with overt bleeding, warrants further prospective investigation.
引用
- Kolte D, Beale C, Aronow HD, et al. Trends and outcomes of red blood cell transfusion in patients undergoing transcatheter aortic valve replacement in the United States. J Thorac Cardiovasc Surg. 2019. PMID: 31014667. doi:10.1016/j.jtcvs.2019.03.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。